SELLAS Life Sciences Group, Inc. has announced positive topline results from its pivotal Phase 3 REGAL trial, which evaluated its immunotherapeutic cancer vaccine, galinpepimut-S (GPS), in patients with acute myeloid leukemia (AML). This development is significant as it demonstrates a statistically meaningful improvement in overall survival for patients who have limited treatment options.
The REGAL trial met its primary endpoint, showing a 41% reduction in the risk of death among patients treated with GPS compared to those receiving the best available treatment. The median overall survival for GPS-treated patients was reported at 24.0 months, compared to 14.7 months for the control group.
SELLAS Life Sciences, incorporated in Delaware, operates within the pharmaceutical preparations sector, specifically focusing on innovative therapies for various cancer types. The company trades on the Nasdaq under the ticker symbol SLS. Recent filings include an 8-K on November 17, 2026, detailing the trial results and an earlier 10-Q on November 12, 2026.
According to the filing, the REGAL trial was designed for patients who achieved a second or later complete remission after second-line salvage therapy and were ineligible for stem cell transplantation. The results indicate that GPS was well tolerated, with adverse events primarily being mild to moderate.
These findings not only impact SELLAS Life Sciences but could also influence the broader pharmaceutical industry, particularly companies developing treatments for AML. The success of GPS may lead to increased competition as other firms strive to enhance their treatment options for this challenging patient population.
Looking ahead, SELLAS plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the results and the regulatory pathway for GPS, with hopes of submitting a Biologics License Application (BLA) in the first half of 2027. This step is crucial for making the treatment available to patients in need.
Read Next
NatWest Group announces final terms for GBP 750 million notes
Walt Disney shifts consumer products to Entertainment segment
Wise Group plc announces share repurchase program
Rentokil Initial PLC Announces Share Buyback Program
Grab Holdings announces 2026 Annual General Meeting date
Amesite Secures New Enterprise Agreement for NurseMagic










